TURN INNOVATIVE SCIENCE INTO VALUE FOR PATIENTS

FY2017 PRESS CONFERENCE

July 11th, 2017 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc.

2

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

3

CHANGES IN THE INNOVATIVE DRUG BUSINESS ENVIRONMENT

Balance between improving access to health and innovation are common challenges across the world

Healthcare changes

  • Aging society

Accelerating innovation

  • Existing high UMNs*

    Decline in profitability of

    • Advances in science technology and information technology

    • Centralization of the national research budget

    • Acceleration of approval processes

      pharmaceutical companies

    • Healthcare cost containment throughout the world

    • Finite product life cycle

    • Increased R&D costs

      Increased difficulty of the drug discovery process

      • Growing complexity of drug targets

      • Need to introduce new technologies and modalities

UMNs: Unmet Medical Needs

4

FINDING OPPORTUNITY

Many opportunities exist where we can provide innovative value to patients

Novel drug discovery in therapeutic areas with high Unmet Medical

Needs

New modalities such as cell and gene therapy

Increasing number of technologies with applicability in various fields

Astellas Pharma Inc. published this content on 12 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 July 2017 02:09:12 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/pdf/170711eg.pdf

Public permalinkhttp://www.publicnow.com/view/98395B4FC73A820D0E4662A4A3E83FF5D76B2887